NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 33,438 Shares

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 33,438 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $26.01, for a total value of $869,722.38. Following the transaction, the insider now owns 10,727,490 shares of the company’s stock, valued at approximately $279,022,014.90. The trade was a 0.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Monday, December 23rd, Nap B.V. Forgrowth sold 25,132 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.49, for a total transaction of $640,614.68.
• On Friday, December 20th, Nap B.V. Forgrowth sold 49,772 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.60, for a total transaction of $1,274,163.20.
• On Wednesday, December 18th, Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $26.10, for a total transaction of $2,629,000.80.
• On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.39, for a total transaction of $4,215,019.29.
• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.08, for a total value of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total value of $213,420.60.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock opened at $25.70 on Wednesday. The firm’s 50 day simple moving average is $22.26 and its two-hundred day simple moving average is $19.26. NewAmsterdam Pharma has a 12-month low of $11.18 and a 12-month high of $27.29.

Institutional Investors Weigh In On NewAmsterdam Pharma

Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its stake in NewAmsterdam Pharma by 176.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock valued at $371,000 after purchasing an additional 14,280 shares during the last quarter. Barclays PLC boosted its position in NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after buying an additional 7,199 shares during the last quarter. Geode Capital Management LLC boosted its position in NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after buying an additional 1,399 shares during the last quarter. M&T Bank Corp increased its holdings in NewAmsterdam Pharma by 54.1% in the 3rd quarter. M&T Bank Corp now owns 27,328 shares of the company’s stock worth $454,000 after buying an additional 9,593 shares during the period. Finally, Frazier Life Sciences Management L.P. raised its position in NewAmsterdam Pharma by 5.1% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock worth $213,396,000 after buying an additional 628,251 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Piper Sandler restated an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Scotiabank upped their price target on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, December 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Needham & Company LLC restated a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Finally, HC Wainwright initiated coverage on shares of NewAmsterdam Pharma in a research report on Monday. They set a “buy” rating and a $48.00 price target for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $38.17.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.